8.01

0.50% -0.04

After Hours: 7.95 -0.06 -0.75%

Adaptive Biotechnologies Corp (ADPT)

Overview News Price History Option Chain Financials Why ADPT Down? Discussions Forecast

Adaptive Biotechnologies Corp stock is traded at $8.01, with a volume of 1.47M. It is down -0.50% in the last 24 hours and up +13.62% over the past month. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Previous Close:

$8.05

Open:

$8.17

24h Volume:

1.47M

Relative Volume:

1.10

Market Cap:

$1.18B

Revenue:

$177.28M

Net Income/Loss:

$-195.24M

P/E Ratio:

-5.9776

EPS:

-1.34

Net Cash Flow:

$-114.54M

1W Performance:

+1.91%

1M Performance:

+13.62%

6M Performance:

+73.75%

1Y Performance:

+112.47%

1-Day Range:

$7.745

$8.31

1-Week Range:

$7.27

$8.31

52-Week Range:

$2.28

$8.33

Adaptive Biotechnologies Corp Stock (ADPT) Company Profile

Name

Adaptive Biotechnologies Corp

Sector

Healthcare (1177)

Industry

Biotechnology (679)

Phone

206-659-0067

Address

1165 EASTLAKE AVE E, SEATTLE, WA

Employee

709

Twitter

@adaptivebiotech

Next Earnings Date

2024-11-07

Latest SEC Filings

ADPT's Discussions on Twitter

Compare ADPT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADPT Adaptive Biotechnologies Corp	8.01	1.18B	177.28M	-195.24M	-114.54M	-1.34
VRTX Vertex Pharmaceuticals Inc	481.16	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	722.07	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	657.97	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	278.25	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	119.94	28.75B	3.30B	-501.07M	1.03B	-2.1146

Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-05-23	Resumed	JP Morgan	Overweight
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight
Aug-25-22	Initiated	Credit Suisse	Underperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Feb-16-22	Reiterated	BTIG Research	Buy
Feb-16-22	Reiterated	BofA Securities	Buy
Feb-16-22	Reiterated	Goldman	Neutral
Feb-16-22	Reiterated	JP Morgan	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-03-20	Initiated	Goldman	Buy
Jul-23-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	BofA/Merrill	Buy
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	Goldman	Neutral
Jul-22-19	Initiated	Guggenheim	Buy
Jul-22-19	Initiated	William Blair	Outperform

View All

Adaptive Biotechnologies Corp Stock (ADPT) Latest News

Feb 06, 2025

It makes sense and dollars to buy Adaptive Biotechnologies Corp (ADPT) stock - SETE News

Feb 06, 2025

Feb 05, 2025

Analysts review Adaptive Biotechnologies Corp’s rating - Knox Daily

Feb 05, 2025